KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Biomarin Pharmaceutical's Cash & Current Investments rose 58.83% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 24.44%. This contributed to the annual value of $1.1 billion for FY2024, which is 5.95% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Cash & Current Investments stood at $1.1 billion for FY2024, which was up 5.95% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Cash & Current Investments ranged from a high of $1.3 billion in FY2022 and a low of $1.0 billion during FY2021.
  • Its 3-year average for Cash & Current Investments is $1.2 billion, with a median of $1.1 billion in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 41.33% in 2020, then fell by 16.86% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Cash & Current Investments stood at $1.1 billion in 2020, then decreased by 4.83% to $1.0 billion in 2021, then rose by 27.39% to $1.3 billion in 2022, then fell by 16.86% to $1.1 billion in 2023, then increased by 5.95% to $1.1 billion in 2024.